U.S. Disposable Syringes Market Size, Share & Trends Analysis Report By Product (Conventional Syringes, Safety Syringes), By Application (Immunization Injections, Therapeutic Injections), By End-use, By States, And Segment Forecasts, 2023 - 2030

Report Overview

The U.S. disposable syringes market size was valued at USD 2,435.64 million in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 5.43% from 2023 to 2030 to reach USD 3,694.39 million by 2030. The growth of U.S. disposable syringes market is attributed due to growing prevalence of chronic disorders, increasing adoption of safety syringes, and growing number of surgeries in U.S. For instance, as projected by the American Heart Association, 45.1% of the U.S. population, or more than 130 million adults, are projected to suffer from some form of CVD by 2035. Moreover, about 655,000 Americans die from heart disease annually, that’s 1 in every 4 deaths.

Healthcare facilities had to use and reuse the same syringe on different patients before the medical sector advanced significantly. This is due to the fact that syringes were not manufactured abundantly and expensive. As a result, it was critical for all doctors/physicians to properly sterilize and sharpen the syringe after each use. Therefore, many chronic diseases began to spread. Due to which demand for U.S. disposable syringes has been increased due to their several benefits over reusable syringes. Several benefits of U.S. disposable syringes are course sterilization and safety. Since the introduction of U.S. disposable syringes, patients no longer have to rely solely on the doctors' sterilization protocols for their safety, as they are discarded after one use. As a result, there is no risk of cross-contamination. Other advantages of U.S. disposable syringes include their low cost and environmental friendliness. As a result of these reasons, the market is predicted to expand.

Moreover, the prevalence of chronic illnesses like Crohn's disease and diabetes, which can be treated with self-injectable medication, is rising. For instance, according to the Diabetes Research Institute Foundation, 10.5% of Americans, or 34.2 million people, have diabetes. There were 26.8 million persons with diabetes, according to estimates. Given their significance during the administration of medications and tests, syringes are necessary for the majority of diagnostic and therapeutic techniques for chronic diseases, driving up demand for the product. Major corporations are also making syringes specifically for the treatment of chronic diseases in an effort to strengthen their market positions, like BD and Smiths Medical. For instance, Chronic conditions are treated with BD's Hypak SCF PRTC glass pre-fillable syringe. Additionally, BD has stated that it intends to spin up its Diabetes Care division as a distinct, publicly traded company in May 2021. BD Diabetes Care, which supports about 30 million patients annually and produces around 8 billion injection devices, has been a significant driver of the adoption of insulin syringes and other products.

Along with the above factors, the need for U.S. disposable syringes in various healthcare settings is likely to increase with its growing aging population, a demographic that is more susceptible to chronic illnesses such as diabetes and other lifestyle-related disorders. Furthermore, as per an article published in Mayo Clinic in 2020, older adult aged 65 years and older take up 16% of the U.S. population. However, they comprise 45% of Emergency Department (ED) visits. Patients in these age brackets are vulnerable to multiple chronic conditions and necessitate greater patient safety & care. These patients frequently suffer from several preexisting diseases. Moreover, alterations in vision & hearing, deterioration in functional reserve, and cognitive impairment are further aggravated by the ED setting which is expected to spur the market growth in near future.

The pandemic, caused by the virus SARS-CoV-2 in the year 2020, has drastically increased the demand for medicines, medical disposable products, emergency supplies, and hospital equipment. Therefore, the COVID-19 outbreak has immensely impacted medical disposables market and is considered to be a highly effective driver for disposable syringes market. With the COVID - 19 outbreak, a huge surge in immunizations is expected. Moreover, the pandemic has also spurred the development of prefilled syringes, especially for low-temperature storage. As a result, due to the outbreak of the COVID-19, the sales of syringes grew significantly.

Additionally, due to syringe shortages, global manufacturing capacity has been increased in a number of nations, including U.S., which has doubled its syringe supply for the COVID-19 immunization campaign in 2021. Moreover, according to the WHO which predicts a 2.0 billion needle deficit through 2022. This is due to increased demand, supply-chain disruptions, and ‘syringe nationalism' are all factors that "may pose substantial hurdles in 2022. As a result, most countries throughout the world have begun to reduce security regulations and resume certain elective treatments, indicating that the market will continue to develop over the projection period. Furthermore, organizations are gaining knowledge in their end-to-end supply chains in order to reduce product prices and improve the quality and services associated with disposable syringes. Such operational ideas help organizations save money by eliminating third-party expenses. These characteristics are projected to generate lucrative market growth prospects.

Manufacturers are focused on efficient sterilizing procedures to avoid infections among healthcare practitioners and patients in the wake of the rapidly spreading COVID-19 pandemic. As a result, firms in the U.S. disposable syringes market are focusing on improving operational performance in order to increase their U.S. credibility. For instance, in June 2021, to support global COVID-19 immunization efforts, BD, a multinational medical technology company, announced that it has received pandemic orders for 2 billion injectable devices in syringes and needles. This new milestone reflects assurances from governments around the world, including Australia, the UK, Canada, Brazil, Germany, France, the Philippines, India, South Africa, Spain, Saudi Arabia, and the U.S., as well as non-governmental organizations that support vaccine deployment in developing countries. These characteristics are projected to generate lucrative market growth prospects.

An increase in the number of surgical procedures/hospital visits, well-established healthcare infrastructure, and favorable reimbursement & regulatory rules in the healthcare industry are expected to present significant states growth opportunities in the market. For instance, according to Centers for Medicare & Medicaid Services (CMS), the health spending in the U.S. is expected to grow at 5.5% every year from 2018 to 2027 and is estimated to reach USD 6 trillion by 2027. In addition, high disposable income in developed economies and availability of skilled professionals are some factors responsible for the large share of the state’s market.

Product Insights

The safety syringes led the market and accounted for more than 63.45% share of the U.S. revenue in 2022. The safety syringes are majorly used for administering medications by utilizing specialized and standard techniques. The unsafe injection practices lead to almost 33,800 HIV infections, 315,000 hepatitis C transmissions, and 1.7 million hepatitis B infections every year globally. Unsafe practices such as multiple use of a syringe & needle without taking precautionary measures as guided by the healthcare professionals lead to needlestick injuries. In addition, conventional disposable syringes provide protection to the recipient, but do not assure the safety of patients. Such factors are anticipated to boost the segment growth.

The WHO has issued guidelines for the use of safety syringes to prevent needlestick injuries. The aim of these guidelines is to prevent the reuse of conventional syringes. The International Organization for Standardization (ISO) has also issued a set of requirements for manufacturers of safety syringes to ensure safety and high performance level of the products.

The conventional syringes are the second leading segment in 2022. Conventional syringes are mostly made of plastic with visible graduation and are intended for single use. Some of the advantages of disposable conventional syringes are that they eliminate the risk of infections from blood-borne pathogens, such as HIV, Ebola virus, and Hepatitis B & C. However, less use of disposable conventional syringes & needles in undeveloped countries due to high additional costs for maintenance may hamper the segment growth. The governments in these countries are undertaking initiatives to increase the use of conventional disposable syringes & needles with an aim to reduce the transmission of diseases in patients; thereby, propelling the segment growth over the forecast period.

Application Insights

The therapeutic injections led the market and accounted for more than 85.72% share of the U.S. revenue in 2022. Increasing awareness toward blood donations in the country is one of the major factors for driving the segment. For instance, as per the America’s Blood Centers, approximately 3 percent of the U.S. population donates blood each year. There were approximately 7.3 million donors in 2019. High prevalence of diseases such as AIDS, tuberculosis, malaria, and dengue leads to demand for high volume of injections as they are one of the essential requirements for diagnosis and treatment.

Furthermore, developments in drugs and delivery systems is also expected to propel the segment growth. For instance, in 2022, CytoDyn, Inc. has completed phase 3 clinical trial of their injectable HIV drug. This injectable is expected to replace the daily antiretroviral pill dose with once-a-week injection, thus improving the quality of life of the 33.00 million people living with AIDS. The success of this drug is expected to provide great opportunity for the growth of disposable syringes market over the forecast period.

The immunization injections segment is anticipated to witness the fastest growth over the forecast period. The process of vaccination is majorly a mass activity, thus, increasing the risk of transmission of blood-borne pathogens. In such cases, the multiple use of a syringe & needle needs to be avoided to prevent the risk of needlestick injuries. In addition, the type of injections used depends on the safety, cost, and type of vaccine to be administered. Prefilled auto-disable syringes are majorly preferred, provided all the vaccines are available in a prefilled form. This prevents vaccine contamination, increases the accuracy of dose, and reduces the waste generated due to multiple vials.

End-use Insights

The hospitals led the market and accounted for more than 34.85% share of the U.S. revenue in 2022. Hospital institutions are the largest market for disposable syringes as they cater to majority of the population at any given time. In terms of volume of disposable syringes, hospitals are observed to be the largest consumer of related products and services. Furthermore, hospitals are considered significant buyers because they have long-term contracts with providers of disposable syringes, which gives them higher negotiation leverage and makes them a larger market for product after-sales services. Furthermore, the increasing rate of hospitalization due to rise in trauma cases, & other infectious diseases; growing number of well-furnished, well-equipped, & advanced hospitals; aging population; and increasing prevalence of chronic diseases are expected to drive the segment growth

The other segment is anticipated to witness the fastest growth over the forecast period. The others section includes academic & medical research centers, ambulatory surgical centers, and defense forces. Increasing healthcare expenditure can boost the number of research centers and academics, owing to which, this segment is anticipated to witness growth over the forecast period. The need for optimum sterility and accuracy in research procedures has resulted in increased demand for sterile disposable syringes in academic and medical research centers. Sterility is of utmost importance in research centers, owing to increasing awareness about possible contamination and increase in academic & research centers. Furthermore, the FDA and other regulatory bodies has set guidelines to review the safety and sterility practices in research labs, which is expected to boost segment growth.

States Insights

Texas dominated the market and accounted for over 8.22% share of U.S. revenue in 2022. This is due to the fact that there are many uninsured adults in these states, a high rate of preventable deaths, lack of investment in public health, a large number of people with mental illness who cannot access care, and rising insurance costs that make healthcare more expensive than in many other regions of the country.

In addition, Texas saw the most increase in population—4 million—of any state over the preceding 10 years. Due to difficulties for residents of the state to access and afford the healthcare services. Texas ranked 42nd overall on assessment of the functioning of the healthcare system. Its residents are less likely to report having a regular source of healthcare, which is a crucial indicator of how effectively the healthcare system is performing. It also has the highest number of uninsured people in the nation.

Texas citizens are most likely to report forgoing needed medical care due to cost, while the state's residents pay a larger proportion of their incomes toward health insurance than residents of nearly every other state. In addition, Texas is one of the 14 states that have not yet expanded Medicaid in accordance with ACA rules, leaving millions of working people without insurance.

California disposable syringes market is anticipated to witness the fastest growth over the forecast. In California, approximately 700 hospitalizations per 100,000 people were possibly preventable through effective chronic care management and access to high-quality primary care, based on a composite measure of hospital admission rates for 8 chronic care conditions. The preventable hospitalization rate varied from high of 1,341 in Butte County. to a low of 129 in Mono County.

U.S. Disposable Syringes Market Share Insights

Companies that sell U.S. disposable syringes are stepping up their efforts to get their products approved so that manufacturers can start mass production. One of the main areas of concern for manufacturers is the avoidance of unintentional needle stick injuries in healthcare settings.

In addition, the market players are adopting various strategies, such as mergers & acquisitions, partnership, product launches and innovations products to strengthen their foothold in the market. For instance, in January 2022 Smith's Medical collaborates with the U.S. government to develop a COVID-19 vaccine. In order to support the Operation Warp Speed immunization programme, the cooperation with BARDA and JPEO-CBRND comprises a USD 20 million investment for enhanced syringe and needle device production, which is expected to enhance market growth in the near future. Some prominent players in the U.S. disposable syringes market include:

• Cardinal Health

• B. Braun Melsungen

• Terumo Corporation

• ICU Medical, Inc. (Smiths Medical)

• Nipro Corporation

• BD

• Sol-Millennium Medical

• CODAN Medizinische Geräte GmbH & Co KG

• Cole-Parmer Instrument Company, LLC. 

• Henke-Sass, Wolf

• UltiMed, Inc.

• Others

U.S. Disposable Syringes Market Report Scope

U.S. Disposable Syringesg Market Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. disposable syringes market report based on product, application, end-use, and state:

• Product Outlook (Revenue USD Million; 2018 - 2030)

  • Conventional Syringes

  • Safety Syringes

    • Retractable Safety Syringes

    • Non-retractable Safety Syringes

• Application Outlook (Revenue USD Million; 2018 - 2030)

  • Immunization Injections

  • Therapeutic Injections

• End-use Outlook (Revenue USD Million; 2018 - 2030)

  • Hospital

  • Diagnostic Laboratories

  • Blood Banks

  • Pharmaceutical industry

  • Veterinary purposes

  • Others

• States Outlook (Revenue, USD Million, 2018 - 2030)

  • Texas

    • Dallas-Fort Worth-Arlington

    • Houston-The Woodlands-Sugar Land

    • San Antonio-New Braunfels

    • Austin-Round Rock-Georgetown

    • McAllen

    • Rest of Texas

  • California

    • Los Angeles-Long Beach-Anaheim

    • San Diego-Chula Vista-Carlsbad

    • San Francisco-Oakland-Berkeley

    • Riverside-San Bernardino

    • Sacramento-Roseville-Folsom

    • Rest of California

  • Florida

    • Miami-Fort Lauderdale-West Palm Beach

    • Tampa-St. Petersburg-Clearwater

    • Orlando-Kissimmee-Sanford

    • Jacksonville

    • North Port-Sarasota-Bradenton

    • Rest of Florida

  • New York

    • New York-Jersey City-White Plains

    • Nassau County-Suffolk County

    • New Brunswick-Lakewood

    • Newark

    • Bridgeport-Stamford-Norwalk

    • Rest of New York

  • Virginia

    • Northern Virginia

    • Hampton Roads

    • Richmond MSA

    • Roanoke MSA

    • Lynchburg MSA

    • Rest of Virginia